Merge pull request decentralized-fda#2 from mikepsinn/v6

merged from dfda website

Author: mikepsinn

.cursorrules

@@ -0,0 +1,20 @@
+Always search the web and hyperlink to the source of information.
+
+Be concise.
+
+Speak plainly.
+
+Use bullet points.
+
+Use numbered lists.
+
+Use tables.
+
+Use bold and italics.
+
+Use hyperlinks. 
+
+DO NOT USE SALESY PROMOTIONAL LANGUAGE. 
+
+Use quantitative facts to support your points wherever possible.
+

.env.example

@@ -1,8 +1,17 @@
 # OpenAI API Configuration
 OPENAI_API_KEY=your_openai_api_key_here
 
+# AWS credentials (if using S3 backup)
+AWS_ACCESS_KEY_ID=
+AWS_SECRET_ACCESS_KEY=
+AWS_REGION=
+S3_PUBLIC_URL=
+
 # AWS Configuration
-AWS_ACCESS_KEY_ID=your_aws_access_key_here
-AWS_SECRET_ACCESS_KEY=your_aws_secret_key_here
-AWS_REGION=your_aws_region_here
-S3_BUCKET_NAME=your_s3_bucket_name_here 
+S3_AWS_BUCKET=
+
+# Optional Image Directory (default: 'img')
+# IMAGE_DIR= 
+
+# Set to false to disable automatic catalog updates from S3 (default: true)
+UPDATE_IMAGE_CATALOG_FROM_S3=false 

01-problem.md

@@ -0,0 +1,67 @@
+# 📖 References
+
+* [Google Spreadsheet of FDA Spending vs Life-Expectancy](https://docs.google.com/spreadsheets/d/e/2PACX-1vTBkVrOYLxloOIADLXA7-k5NBIGgQ\_dfFQ7BLUN0oaJPVQ\_NqdFdVUfhuPkVWgFZ9gfLrwPdjuG1sTn/pubhtml)
+* [Summary of NDA Approvals & Receipts, 1938 to the present](https://www.fda.gov/about-fda/histories-product-regulation/summary-nda-approvals-receipts-1938-present)
+* [Theory, Evidence, and Examples of FDA Harm](https://www.fdareview.org/issues/theory-evidence-and-examples-of-fda-harm/)
+* [DATA](https://docs.google.com/spreadsheets/d/1hltgVd8OO\_nfd9m7FUbbsOTXFX4VbDKuFNw4Cy43f7Q/edit#gid=0)
+* [GDP](https://ourworldindata.org/economic-growth)
+* [Reform, Regulation, and Pharmaceuticals — The Kefauver–Harris Amendments at 50](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101807/)
+* [Consumer Price Index](https://www.bls.gov/regions/midwest/data/consumerpriceindexhistorical\_us\_table.pdf)
+* [Estimates of World GDP, One Million B.C. – Present](https://delong.typepad.com/print/20061012\_LRWGDP.pdf)
+* [Newspaper Generator](https://newspaper.jaguarpaw.co.uk/)
+* [Report suggests drug-approval rate now just 1-in-10](https://www.amplion.com/report-suggests-drug-approval-rate-now-just-1-in-10/)
+* [How many people die and how many are born each year?](https://ourworldindata.org/births-and-deaths)
+* [Gross World Product per capita](http://statisticstimes.com/economy/gross-world-product-capita.php)
+* [History of Clinical Trials](https://en.wikipedia.org/wiki/Clinical\_trial#History)
+* [How many life-years have new drugs saved?](https://academic.oup.com/inthealth/article/11/5/403/5420236)
+* [CATO](https://www.cato.org/publications/commentary/end-fda-drug-monopoly-let-patients-choose-their-medicines)
+* [Medical Innovation](http://valueofinnovation.org/)
+* [Timeline History of Clinical Research](https://www.timetoast.com/timelines/history-of-clinical-research)
+* [FDA and Clinical Drug Trials: A Short History](https://www.fda.gov/media/110437/download)
+* [Do Off-Label Drug Practices Argue Against FDA Efficacy Requirements?](https://www.independent.org/publications/article.asp?id=1302)
+* [Reform Options](https://www.fdareview.org/issues/reform-options/)
+* [Before Occupy: How AIDS Activists Seized Control of the FDA in 1988](https://www.theatlantic.com/health/archive/2011/12/before-occupy-how-aids-activists-seized-control-of-the-fda-in-1988/249302/)
+* [A Brief History of the Center for Drug Evaluation and Research](https://www.fda.gov/about-fda/virtual-exhibits-fda-history/brief-history-center-drug-evaluation-and-research#display\_58)
+* [Milestones in U.S. Food and Drug Law History](https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/milestones-us-food-and-drug-law-history)
+* https://go.drugbank.com/stats
+
+Additional Sources
+
+1. https://www.ahajournals.org/doi/10.1161/strokeaha.111.621904
+2. https://www.fda.gov/media/110437/download
+3. https://www.academia.edu/2801726/Is\_the\_FDA\_safe\_and\_effective
+4. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
+5. https://www.cato.org/commentary/end-fda-drug-monopoly-let-patients-choose-their-medicines
+6. https://www.fda.gov/files/about%20fda/published/The-Sulfanilamide-Disaster.pdf
+7. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act
+8. https://www.fda.gov/media/79922/download
+9. https://www.fda.gov/media/120060/download
+10. https://www.nature.com/articles/549445a
+11. https://www.statista.com/statistics/1041467/life-expectancy-switzerland-all-time/
+12. https://www.statista.com/statistics/195950/infant-mortality-rate-in-the-united-states-since-1990/
+13. https://kof.ethz.ch/en/news-and-events/kof-bulletin/kof-bulletin/2021/07/Improvements-in-Swiss-life-expectancy-and-length-of-life-inequality-since-the-1870s.html
+14. https://docs.google.com/spreadsheets/d/1hltgVd8OO\_nfd9m7FUbbsOTXFX4VbDKuFNw4Cy43f7Q/edit#gid=802845894
+15. https://www.visualcapitalist.com/which-rare-diseases-are-the-most-common/
+16. http://valueofinnovation.org/
+17. https://www.medicinesaustralia.com.au/wp-content/uploads/2020/11/Prof-Frank-Lichtenberg\_session-3.pdf
+18. Anglemyer A., Horvath H.T., and Bero, L. (2014). Healthcare Outcomes Assessed with Observational Study Designs Compared with Those Assessed in Randomized Trials (Review), Cochrane Database of Systematic Reviews, Issue 4, Art No MR000034. doi:10.1002/14651858.MR000034.pub2.
+19. Ball, R., Robb, M., Anderson, S.A., and Dal Pan, G. (2016). The FDA’s Sentinel Initiative—A Comprehensive Approach to Medical Product Surveillance, Clinical Pharmacology & Therapeutics, 99(3):265-268. doi:10.1002/cpt.320. Benson, K. and Hartz, A.J. (2000). A Comparison of Observational Studies and Randomized, Controlled Trials, New England Journal of Medicine, 342:1878-1886. doi:10.1056/NEJM200006223422506.
+20. Berger, M.J, Sox, H., Willke, R.J., Brixner, D.L., Hans-Georg, E., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., Wang, S.V., Watkins, J., and Mullins, C.D. (2017). Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making, Pharmacoepidemiology and Drug Safety, 26(9):1033- 1039. doi:10.1002/pds.4297.
+21. Clinical Trial Transformation Initiative (CTTI) (2017). CTTI Recommendations: Registry Trials. Retrieved from https://www.ctti-clinicaltrials.org/files/recommendations/registrytrials-recs.pdf.
+22. Cooper, C.J., Murphy, T.P., Cutlip, D.E., Jamerson, K., Henrich, W., Reid, D.M., Cohen, D.J., Matsumoto, A.H., Steffes, M., Jaff, M.R., Prince, M.R., Lewis, E.F., Tuttle, K.R., Shapiro, J.I., Rundback, J.H., Massaro, J.M., D’Agostino, R.B., and Dworkin, L.D. (2014). Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis, New England Journal of Medicine, 370(1):13-22. doi:10.1056/NEJMoa1310753.
+23. Eapen, Z.J., Lauer, M., and Temple, R.J. (2014). The Imperative of Overcoming Barriers to the Conduct of Large, Simple Trials. Journal of the American Medical Association, 311(14): 1397-1398. doi:10.1001/jama.2014.1030. Eworuke, E. (2017). Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Risk of Seizures Associated with Ranolazine \[Power Point Presentation]. Retrieved from https://www.sentinelinitiative. orghttps://aspe.hhs.gov/sites/default/files/communications/publications-presentations/Sentinel-ICPE-2017-Symposium-Snapshotof-the-First-Year\_Ranexa-Seizures.pdf.
+24. Food and Drug Administration, Center for Medicare Services, and Acumen Team. (2018). Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices Meeting: Relative Effectiveness of Cell-cultured versus Egg-based Influenza Vaccines, 2017-18 \[Power Point Presentation]. Retrieved from https://www.cdc.gov/ vaccines/acip/meetings/downloads/slides-2018-06/flu-03-Lu-508.pdf. Ford, I. and Norrie, J. (2016). Pragmatic Trials. New England Journal of Medicine, 375:454-463. doi:10.1056/ NEJMra1510059.
+25. Fralick, M., Kesselheim, A.S., Avorn, J., and Schneeweiss, S. (2018). Use of Health Care Databases to Support Supplemental Indications of Approved Medications, JAMA Internal Medicine, 178(1): 55-63. doi:10.1001/ jamainternmed.2017.3919
+26. Franklin, J.M., and Schneeweiss, S. (2017). When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials, Clinical Pharmacology & Therapeutics, 102(6):924-933. doi:10.1002/cpt.857.
+27. Fröbert, O., Lagerqvist, B., Olivecrona, G., Omerovic, E., Gudnason, T., Maeng, M., Aasa, M., Angerås, O., Calais, F., Danielewicz, M., Erlinge, D., Hellsten, L., Jensen, U., Johansson, A.C., Kåregren, A., Nilsson, J., Robertson, L., Sandhall, L., Sjögren, I., Östlund, O., Harnek, J., and James, S.K. (2013). Thrombus Aspiration during STSegment Elevation Myocardial Infarction, New England Journal of Medicine, 369:1587-1597. doi:10.1056/ NEJMoa1308789.
+28. Guadino, M., Di Franco, A., Rahouma, M., Tam, D.Y., Iannaccone, M., Deb, S., D’Ascenzo, F., Abouarab, A.A., Girardi, L.N., Taggart, D.P., and Fremes, S.E. (2018). Unmeasured Confounders in Observational Studies Comparing Bilateral Versus Single Internal Thoracic Artery for Coronary Artery Bypass Grafting: A Meta-Analysis, Journal of the American Heart Association, 7:e008010. doi.org/10.1161/JAHA.117.008010.
+29. Gliklich, R.E., Dreyer, N.A., and Leavy, M.B., editors. (2014). Registries for Evaluating Patient Outcomes: A User’s Guide \[Internet]. 3rd edition. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Apr. 1, Patient Registries. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK208643.
+30. Hemkens, L.G., Contopoulos-Ioannidis, D.G., and Ioannidis, J.P. (2016). Agreement of Treatment Effects for Mortality from Routinely Collected Data and Subsequent Randomized Trials: Meta-Epidemiological Survey, BMJ, 352:i493. doi:10.1136/bmj.i493.
+31. Hernandez, A.F., Fleurence, R.L., and Rothman, R.L. (2015). The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm, Annals of Internal Medicine, 163(8):635-636. doi:10.7326/M15-1460.
+32. Izurieta, H.S., Thadani, N., Shay, D.K., Lu, Y., Maurer, A., Foppa, I.M., Franks, R., Pratt, D., Forshee, R.A., MaCurdy, T., Worrall, C., Howery, A.E., and Kelman, J. (2015). Comparative Effectiveness of High-dose versus Standarddose Influenza Vaccines in US Residents Aged 65 Years and Older from 2012 to 2012 Using Medicare Data: a Retrospective Cohort, Lancet Infect Dis, 15(3):293-300. doi:10.1016/S1473-3099(14)71087-4.
+33. Izurieta, H.S., Wernecke, M., Kelman, J., Wong, S., Forshee, R., Pratt, D., Lu, Y., Sun, Q., Jankosky, C., Krause, P., Worrall, C., MaCurdy, T., Harpaz, R. (2017). Effectiveness and Duration of Protection Provided by the Liveattenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older, Clinical Infectious Diseases, 64(6):785-793. doi.org/10.1093/cid/ciw854.
+34. Khozin, S., Abernethy, A.P., Nussbaum, N.C., Zhi, J., Curtis, M.D., Tucker, M., Lee, S.E., Light, D.E., Gossai, A., Sorg, R.A., Torres, A.Z., Patel, P., Blumenthal, G.M., and Pazdur, R. (2018). Characteristics of Real-World Metastatic Non-small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval, Oncologist, 23(3): 328-336. doi: 10.1634/theoncologist.2017-0353.
+35. Maggiono, A.P., Franzosi, M.G., Fresco, C., Turazza, F., and Tognoni, G. (1990). GISSI Trials in Acute Myocardial Infarction, CHEST Journal, 97(4), Supplement: 146S-150S. doi:10.1378/chest.97.4\_Supplement.146S
+36. [Historical Changes in Causes of Death - Sociological Images (thesocietypages.org)](https://thesocietypages.org/socimages/2012/06/25/historical-changes-in-causes-of-death/)
+37. [Causes of Death - Our World in Data](https://ourworldindata.org/causes-of-death)]
+38. [NVSS - Mortality - Historical Data (cdc.gov)](https://www.cdc.gov/nchs/nvss/mortality\_historical\_data.htm)

02-solution.md

@@ -0,0 +1,102 @@
+# Decentralized FDA (DFDA) Platform Wiki
+
+This repository contains comprehensive documentation for the Decentralized FDA (DFDA) platform, a global initiative to automate and decentralize clinical research for quantifying the effects of foods and drugs worldwide.
+
+## Project Overview
+
+The DFDA platform aims to revolutionize how we understand the effects of foods and drugs through:
+- Decentralized clinical trials
+- Real-world evidence collection
+- Automated data analysis
+- Community-driven research
+- Transparent validation processes
+
+## Repository Structure
+
+```
+├── docs/                      # Core platform documentation
+│   ├── architecture/         # System architecture and design
+│   ├── governance/          # DAO and protocol governance
+│   ├── api/                 # API documentation
+│   ├── getting-started/     # Quick start guides
+│   └── contributing/        # Contribution guidelines
+│
+├── clinical-trials/          # Clinical trial documentation
+│   ├── protocols/           # Standard trial protocols
+│   ├── methodologies/       # Research methodologies
+│   ├── templates/           # Trial templates and forms
+│   ├── validation/          # Validation procedures
+│   └── decentralized-methods/ # Decentralized trial methods
+│
+├── data-standards/          # Data standardization
+│   ├── schemas/            # Data schemas and models
+│   ├── ontologies/         # Medical and research ontologies
+│   └── interoperability/   # Data exchange standards
+│
+├── analytics/              # Analysis documentation
+│   ├── models/            # Analytical models
+│   ├── algorithms/        # Analysis algorithms
+│   └── validation/        # Validation methods
+│
+├── platform/              # Platform components
+│   ├── smart-contracts/   # Smart contract documentation
+│   ├── security/         # Security protocols
+│   ├── integration/      # Integration guides
+│   ├── features/         # Feature documentation
+│   └── plugins/          # Plugin documentation
+│
+├── regulatory/           # Regulatory documentation
+│   ├── frameworks/      # Regulatory frameworks
+│   ├── compliance/      # Compliance guidelines
+│   ├── legal/          # Legal documentation
+│   └── privacy/        # Privacy and data protection
+│
+├── knowledge-base/      # Knowledge repository
+│   ├── interventions/  # Food and drug interventions
+│   ├── conditions/     # Medical conditions
+│   ├── biomarkers/     # Biomarker documentation
+│   └── research-database/ # Research findings
+│
+├── community/          # Community documentation
+│   ├── governance/    # Community governance
+│   ├── partnerships/  # Partner documentation
+│   ├── incentives/    # Incentive mechanisms
+│   └── case-studies/  # Success stories
+│
+├── technical/         # Technical documentation
+│   ├── infrastructure/ # Infrastructure docs
+│   ├── deployment/    # Deployment guides
+│   ├── maintenance/   # Maintenance procedures
+│   └── monitoring/    # System monitoring
+│
+├── assets/           # Project assets
+│   ├── images/      # Image assets
+│   ├── diagrams/    # Technical diagrams
+│   ├── presentations/ # Presentation materials
+│   └── media/       # Media files
+│
+└── supporting-materials/ # Additional resources
+    ├── research-papers/ # Academic research
+    ├── white-papers/   # White papers
+    ├── presentations/  # Presentations
+    └── use-cases/     # Use case documentation
+```
+
+## Getting Started
+
+1. Visit the `/docs/getting-started` directory for initial setup and orientation
+2. Review the governance model in `/docs/governance`
+3. Understand our data standards in `/data-standards`
+4. Explore the clinical trial protocols in `/clinical-trials/protocols`
+
+## Contributing
+
+We welcome contributions from researchers, developers, and healthcare professionals. Please see `/docs/contributing` for guidelines.
+
+## License
+
+This project is licensed under [appropriate license] - see the LICENSE file for details.
+
+## Contact
+
+[Contact information and community channels] 

12-references.md

@@ -0,0 +1,23 @@
+# Table of contents
+
+* [💊 The Decentralized FDA](README.md)
+* [📘 Historical Evidence Supporting Decentralized Efficacy Trials](historical-evidence-supporting-decentralized-efficacy-trials.md)
+* ☠️ Problems With the Current Model
+  * [🥫 No Data on Unpatentable Molecules](problems/no-data-on-unpatentable-molecules.md)
+  * [💰 Clinical Research is Expensive](problems/clinical-research-is-expensive.md)
+  * [🥸 Trials Often Aren't Representative of Real Patients](problems/trials-often-arent-representative-of-real-patients.md)
+  * [❓ We Know Next to Nothing](problems/page-1.md)
+  * [⏱️ Deaths Due to US Regulatory "Drug Lag"](problems/deaths-due-to-us-regulatory-drug-lag.md)
+  * [🙈 Negative Results are Never Published](problems/negative-results-are-never-published.md)
+  * [🎭 Conflicts of Interest](problems/conflicts-of-interest.md)
+  * [🗓️ No Long-Term Outcome Data](problems/no-long-term-outcome-data.md)
+  * [📃 Lack of Incentive to Discover the Full Range of Applications for Off-Patent Treatments](problems/lack-of-incentive-to-discover-the-full-range-of-applications-for-off-patent-treatments.md)
+  * [🤒 People With Rare Disease are Severely Punished](problems/people-with-rare-disease-are-severely-punished.md)
+  * [🔮 Pre-Determining Clinical Endpoints Requires Psychic Powers](pre-determining-clinical-endpoints-requires-psychic-powers.md)
+* [🎯 Benefits of a Decentralized Model](02-solution)
+  * [🎭 More Cures and Less Lifelong Attempts at Masking Symptoms](more-cures-and-less-lifelong-attempts-at-masking-symptoms.md)
+  * [🧐 Greater Competitive Innovation and Fewer Monopolies](greater-competitive-innovation-and-fewer-monopolies.md)
+  * [👀 Lower Costs of Validated Observational Research for Efficacy](lower-costs-of-validated-observational-research-for-efficacy.md)
+  * [📈 Impact of Innovative Medicines on Life Expectancy](2-solution/impact-of-innovative-medicines-on-life-expectancy.md)
+  * [🌎 Cost Savings from Decentralized Clinical Trials](cost-savings-from-decentralized-clinical-trials.md)
+* [📖 References](12-references.md)